September 20, 2021 5:01pm

The Biostage (BSTG) Chronicles: On Monday, 563 dropped the share price -$0.26 to $3.40 after Friday, 229 traded shares dropped the share price -$0.38 to $3.63 after Thursday’s -$0.04 with 461 shares traded, suddenly 14,641 were traded with the shares down -$0.04. Proves my facts of the “pump/promote” actions; why hasn’t the SEC questioned who or which entity is buying these shares – there is a definite pattern?

Preopen indication results: 6 Hits and 0 MISS

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own “rules”, I set-up my own “warning analysis” which isn’t machine oriented!  

The Dow closed DOWN -614.41 points (-1.78%); the S&P closed DOWN -75.26 points (-1.70%) while the Nasdaq closed DOWN -330.06 points (-2.19%)

 

Henry’omics:

U.S. stocks began the week deeply in the red as electronic trading lost faith in our sector in the fourth (4th) week of September amid emerging risks for the market.

Mike Wilson, Morgan Stanley’s chief U.S. equity strategist. “We point to downside risk to earnings revisions, consumer confidence and PMIs.” Wilson said he believes a “destructive outcome” is looking more likely that results in a pullback of 20% or more. On Friday, University of Michigan’s September consumer sentiment index came in at 71, just slightly above the August level that was the lowest in 9 years. <CNBC>

The Cboe Volatility index, Wall Street’s fear gauge, jumped above the 25 level on Monday, the highest since May.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Monday opened negative at 3/30, 1 flat and 1 acquired, stayed negative at the mid-day at 2/32 and 1 acquired, ending with a negative close of 1/33 and 1 acquired;
  • Friday opened negative at 11/20, 3 flats and 1 acquired, flipped positive at the mid-day at 18/16 and 1 acquired, closing positive at 28/6 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “the battle for sentiment lost. The oversold versus the overbought brought-on by electronic trading. The Cboe Volatility index, the dreaded fear gauge, jumped above the 25 level on Monday, the highest since May.” … https://www.regmedinvestors.com/articles/12101

 

Pre-0pen Results: 6 Hits <Verastem (VSTM +$0.05); CRISP Therapeutics (CRSP -$8.05), Editas Medicine (EDIT - $5.00),  Intellia Therapeutics (NTLA -$8.93), Fate Therapeutics (FATE -$4.40), Biostage (BSTG -$0.26)> 0 MISS

 

The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23
  • Applied Genetic Technologies (AGTC) reports 9/23

 

Key Metric - volume:

  • Sector volume was NEGLIDGIBLE with 1 of the 1-upside having higher than the 3-month average volume with MODERATE volume of 11 of 33-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: WHAT happened to the usual “pump/promote”?

Monday closed down -$0.26 to $3.40 with 563 shares traded after ...

Last Friday’s 129 shares traded dropping the share price -$0.38 after Thursday closed -$0.04 with 14,641 shares traded after Wednesday opened down -$0.04 (404 shares traded) and then promptly jumped +$0.52 with 17,107 shares traded after Tuesday closed down -$0.27 to $3.56 with 6,551 shares traded following Monday’s +$0.04 to $3.83 with 26,150 shares traded,

The previous Friday closed down -$0.19 to $3.79 with 22,124 shares traded after Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded, Wednesday traded +$0.57 with 7,833 shares traded after last Tuesday closing down -$0.75 to $2.75 with 6,705 shares traded.

  • Today again establishes the fact of how BSTG’s share trades with and without the “push/promote”,
  • WERE BSTG’s Q2 filing AUDITED or UNAUDITED for investors?

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Verastem Oncology (VSTM) to name 1 of the 1 inclining of the 35 covered

Hammered in today’s market:

  • Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), Editas Medicine (EDIT), Fate Therapeutics (FATE) to name 5 of the 33 declining of the 35 covered

Closing flat:

  • 1 – Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -2.13% and XBI closed down -3.10%
  • Friday, the IBB closed up +0.64% and XBI closed up +1.44%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +4.90 points or +23.55% at 25.71
  • Friday was up +2.12 points or +11.34% at 20.41

 

September, the third month of Q3/21:

Monday (9/20) closed negative with 1 advancer, 33 decliners and 1 acquired

Friday closed positive with 28 advancers, 6 decliners and 1 acquire

 

The BOTTOM LINE: What changes or more I can write, when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

The stem, cell and gene therapy sector is vulnerable to what could be extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, the facts and truth need to be recognized!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.